lead position
Sponsored content
Sponsored by
Maiwald
Features list
-
Phillip Bausk explains the US patent reforms under the America Invents Act and how the life sciences industry is adapting to them
-
The head of patent litigation outside the US, Jurgen Dressel has always stood out for his willingness to discuss the issues driving his industry. He tells James Nurton why litigation will increase and the “whittling away” of rights in many countries
-
The subject of gene patentability is one of the most controversial topics in life sciences. In June 2013, the US Supreme Court reached a unanimous decision in the Association for Molecular Pathology v Myriad Genetics. It stated that companies cannot patent parts of naturally occurring human genes. Managing IP sat down with Fitzpatrick Cella Harper & Scinto attorneys Robert Fischer, John Carlin and Joshua Rothman to discuss the ruling
-
Dechert attorneys Christine C Levin and Irene Ayzenberg-Lyman provide an overview of the recent US Supreme Court decision, FTC v Actavis
-
Daniel Sanchez and Victor Ramirez of Olivares report on new guidelines in Mexico that change the criteria for pharmaceutical trade marks during the prosecution of market authorisations
-
EPO President Benoît Battistelli explains why he is proud of the achievements of the EPC, discusses what challenges remain, and explains why the planned unitary patent is the fulfilment of the founders’ vision
Local Insights